

The Influence of Wharton Jelly Mesenchymal Stem Cell toward Matrix Metalloproteinase- 13 and RELASynoviocyte Gene Expression on Osteoarthritis

by Gustirevila Gustirevila2

Submission date: 13-Sep-2021 01:16PM (UTC+0800)

Submission ID: 1647150675

File name: nase-13and_RELASynoviocyte_Gene_Expression_on_Osteoarthritis.pdf (530.2K)

Word count: 4350

Character count: 24118

The Influence of Wharton Jelly Mesenchymal Stem Cell toward Matrix Metalloproteinase-13 and *RELA* Synoviocyte Gene Expression on Osteoarthritis

Vivi Sofia^{1,2*}, Ellyza Nasruf³, Menkher Manjas⁴, Gusti Revilla⁵

¹Postgraduate Biomedical Science, Faculty of Medicine, Andalas University, Padang, Indonesia; ²Faculty of Pharmacy Ahmad Dahlan University, Jogjakarta, Indonesia; ³Department of Clinical Pathology, Faculty of Medicine, Andalas University, Indonesia; ⁴Department of Orthopedic Surgery, Faculty of Medicine, Andalas University, Indonesia; ⁵Department of Anatomy, Faculty of Medicine, Andalas University, Indonesia

Abstract

Citation: Sofia V, Nasruf E, Manjas M, Revilla G. The Influence of Wharton Jelly Mesenchymal Stem Cell toward Matrix Metalloproteinase-13 and *RELA* Synoviocyte Gene Expression on Osteoarthritis. Open Access Maced J Med Sci. 2019 Mar 15; 7(5):701-706. https://doi.org/10.3889/oamjms.2019.157

Keywords: Matrix Metalloproteinase-13; *RELA*; Mesenchymal Stem Cell Wharton Jelly; Co-culture

***Correspondence:** Vivi Sofia, Faculty of Medicine, Andalas University, Padang, Indonesia. E-mail: vivis554@gmail.com

Received: 09-Dec-2018; **Revised:** 06-Feb-2019; **Accepted:** 07-Feb-2019; **Online first:** 27-Feb-2019

Copyright: © 2019 Vivi Sofia, Ellyza Nasruf, Menkher Manjas, Gusti Revilla. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)

Funding: This research did not receive any financial support

Competing Interests: The authors have declared that no competing interests exist

BACKGROUND: Therapy for osteoarthritis (OA) with satisfactory results has not been found to date. In OA pathogenesis, *RELA* gene involved in cartilage degradation and MMP-13 in degrade cartilage, as a member family of NF- κ B genes, *RELA* serves to modulate inflammatory responses and activates pro-inflammatory cytokines.

AIM: This study aims to identify the influence of Wharton Jelly Mesenchymal Stem Cell (MSC-WJ) on *MMP-13* and *RELA* expression gene in synoviocyte by in vitro.

MATERIAL AND METHODS: This research is pure experimental research. The sample used derived from synovial tissue of OA patients who underwent Total Knee Replacement (TKR) surgery. This study was divided into six groups treated with 4 replications. Group I and II (control groups) were synoviocyte of OA incubated for 24 and 48 hours, respectively. Group III and IV were MSC-WJ incubated for 24 and 48 hours, respectively. Group V and VI were Synoviocyte-MSC-WJ co-culture group incubated for 24 and 48 hours, respectively. Identification of *MMP-13* and *RELA* gene expression in each group was performed by using qPCR.

RESULT: The results showed that MSC-WJ reduced *MMP-13* gene expression after co-culture for 24 and 48 hours in OA synoviocyte. The highest gene expression of *MMP-13* was in Group I and II (1.00 ng/ μ l), followed by Group III (0.41 ng/ μ l), Group IV (0.24 ng/ μ l), Group V (0.13 ng/ μ l), and Group VI (0.04 ng/ μ l). MSC-WJ administration also decreased *RELA* gene expression. The highest gene expression of *RELA* gene was in Group I and II (1.00 ng/ μ l), Group V (0.67 ng/ μ l), Group III (0.58 ng/ μ l), Group IV (0.16 ng/ μ l), and Group VI (0.16 ng/ μ l).

CONCLUSION: This study concluded that MSC-WJ in OA synoviocyte significantly reduced the expression of *MMP-13* and *RELA* gene (p <0.05).

Introduction

Osteoarthritis (OA) is a local disease, caused by primary and secondary degenerative disorders due to "wear and tear" and ageing process [1]. According to the World Health Organization (2004), the prevalence of OA in the world reached 151.4 million people, and about 27.4 million people were in the Southeast Asia region. In Indonesia, 8.1% of the total population experienced OA [2].

At the molecular level, the imbalance between

catabolic and anabolic in the joint cartilage causes OA [3]. The expression of several genes involved in inflammatory responses and cartilage degradation, such as IL-1 and TNF- α , is regulated predominantly by Nuclear Factor Kappa Beta (NF- κ B). NF- κ B stimulates TNF- α and IL-1 β cytokines which contribute to the inflammatory process in OA. NF- κ B is also important in the transcription process of *MMP-13* gene [4], [5]. *RELA* is a subunit of the NF- κ B p65 gene which plays an important role in the pathogenesis of OA.

In the last decade, stem cell research has

shown rapid progress. The stem cells were employed to identify growth and development process of human body tissues, and the pathogenesis of diseases suffered

This study aims to investigate the influence of Wharton Jelly Mesenchymal Stem Cell (MSC-WJ) on Matrix Metalloproteinase-13 and *RELA* gene expression in synoviocyte by *in vitro*.

Material and Method

A pure experimental study was divided into six treatment groups with four replications. Group I and II (control groups) were synoviocyte of OA incubated for 24 and 48 hours, respectively. Group III and IV were Mesenchymal Stem Cell-Wharton Jelly incubated for 24 and 48 hours, respectively. Group V and VI were synoviocyte- Mesenchymal Stem Cell-Wharton Jelly co-culture group incubated for 24 and 48 hours, respectively. Each treatment group consisted of 10^5 cells, each for synoviocyte and Mesenchymal Stem Cell-Wharton Jelly cells. Mesenchymal Stem Cell-Wharton Jelly derived from IMERI (Indonesian Medical Education and Research Institute) Faculty of Medicine, University of Indonesia. Synoviocyte is derived from synovial tissue of OA grade IV underwent Total Knee Replacement (TKR) surgery at Public Hospital Dr M. Djamil Padang, Indonesia. The experimental synoviocyte were the results of the 3rd passage cell culture. The samples taken did not use informed consent because the samples used were stored biologically after post-knee joint surgery Osteoarthritis Grade IV. Samples were taken from six patients with male sex aged 40-70 years.

Isolation of OA primary cells

Synovial tissue and search are obtained from OA patients after Total Knee Replacement (TKR). Ten samples were used for experiments. Synovial tissue is planted in the well plate with 10% Fetal Bovine Serum (FBS), 1% penicillin/streptomycin and 1% fungizone in Dulbecco's Modified Eagle's Medium (DMEM, Life Technologies) which is planted with an explant planting system. Cells were sub-cultured three times, and the result of 3rd sub-culture was used for treatment. Each experiment was repeated for three times.

Coculture of stem cells with OA primary cells

OA primary cells were cultured with 50–60% confluence, then cultured together with mesenchymal stem cells from Wharton Jelly. The cells were

observed for 24 and 48 hours and calculated with Haemocytometer with 10^5 cells/well.

Table 1: Primer Design

No. Primer Nucleotide Sequence NM Amplicon	NCBI Accession Size	Number Gene
1. MMP-13F 5'-CACTTTATGCTTACTGATGACG-3'	NM_002427.3	154 bp
2. MMP-13R 5'-TCCTCGGAGACTGGTAATGG-3'	NM_002427.3	154 bp
3. <i>RELA</i> F 5'-CGCATCCAGACCAACAACA-3'	NM_001243984.1	154 bp
4. <i>RELA</i> R 5'-AGATGGGATGAGAAAGGACAGG-3'	NM_001243984.1	154 bp
5. HPRT1 5'-CCTGGCGTCGTGATTAGTGAT-3'	NM_000194.2	158 bp
6. HPRT1 5'-CCCATCTCCTTCATCACATCTC-3'	NM_000194.2	158 bp

RNA extraction and cDNA synthesis

RNA was extracted from the isolates of synovial tissue grade IV from OA patients with TRIzol® (Invitrogen, USA) according to the manufacturer's protocol. The quantity of RNA was calculated by NanoDrop. Synthesis of cDNA was performed by using iScript cDNA Synthesis Kit (BioRad, USA) on thermal cycler C1000 (BioRad, USA) Reverse Transcriptase PCR (RT-PCR) devices. The reaction of cDNA synthesis was 5 µg total RNA, 1 x RT buffer, 20 pmol oligodT, 4 mM dNTP, 10 mM DTT, 40 U TMII RTase and H₂O-DEPC SuperScript enzymes with a total volume of 20 µl. The cDNA synthesis was performed at 52°C for 50 min according to the manual kit protocol (Biorad, USA).

PCR Gradient Amplification

DNA was amplified with SYBR Green amplification kits. The PCR program was 95°C pre-denaturation for 30 sec, followed by 5-sec denaturation, gradient annealing at 55°C for 5 sec for 50 cycles, additional melting curve 65-95°C with an increase of 0.5°C every 5 sec.

Measurement of gene concentration

The measurement of gene concentration in this study was the relative quantification method (Livak-Schmittgen, 2001) [5].

$$\Delta C_{T \text{ experiment}} = C_{T \text{ experiment target}} - \text{experiment housekeeping}$$

$$\Delta C_{T \text{ control}} = C_{T \text{ control target}} - \text{control housekeeping}$$

$$\Delta \Delta C_{T \text{ experiment}} = \Delta C_{T \text{ experiment}} - \Delta C_{T \text{ control}}$$

The comparison of gene expression levels = $2^{\Delta \Delta C_{T}}$. The measurement of gene concentration was by using LightCycler® software program referred to Livak formula (concentration in picogram size). HPRT1 gene was a housekeeping gene, and calibrator gene was from the control group.

Research Ethics

This study was already passed the ethics clearance and has been approved by the Ethics Committee of the Faculty of Medicine, Andalas University, Padang with registration number: 550/KEP/FK/2017 (Attached).

Statistical analysis

Normality test for MMP-13 and *RELA* gene expression was performed using Saphiro Wilk Test and homogeneity test with Levene test. The data is normally distributed if p-value > 0.05 and homogenous if p-value > 0.05. For *MMP-13* gene expression, normally distributed and homogeneous data were analysed with ANOVA Test and Tukey's HSD Post hoc Test. For *RELA* gene expression, the data were not normally distributed, and homogeneous were analysed with a non-parametric test (Kruskal Wallis test) then followed by Mann Whitney Test [6].

Results

Sample Characteristics

The result of synoviocyte isolation from synovial tissue was fibroblast-shaped cells, cultured in a plate. The morphology of synoviocyte is presented in Figure 1.




Figure 1: Morphology cells (A) Cell synoviocyte and (B) MSC-WJ

In each passage, cell morphology is like a fibroblast cell, a nucleus located in the middle of the cell and attaches to the base of the flask containing a complete medium.




Figure 2: Morphology of synoviocyte co-culture MSC-WJ (A) Co-culture 24 hour and (B) Co-culture 48 hour

The optimisation of RT-PCR was presented in Figure 4. The *MMP-13* target gene is well-amplified (Figure 4A). The melting peak graph (Figure 4B) of *MMP-13* primer optimisation was sharp and homogeneous peaks.




Figure 3: Data on Characteristics of Mesenchymal Stem Cells Wharton Jelly. (A) Cells MSC-WJ reach confluence. Scale bar: 500 μ m. Photographs of cells taken using a Nikon Ti-S microscope. (B) Data flow cytometry. Forward scatter (FCS) plot & side scatter (SSC) plot. Population gated events (P1): 20,000. (C) Cell surface markers expression: CD73-APC 99.8% and CD105- PerCP-Cy5.5 95%. (D) Cell surface markers expression: CD90-FITC 99.9% and Lin (-) - PE 0.4%

Electrophoresis was performed to confirm the result of primer optimisation in Figure 5. The results of RT-PCR optimisation for *RELA* genes and *HPRT1* as the housekeeping gene, as shown in Figure 6 and confirmed with electrophoresis on agarose gel 0.5% in Figure 7.




Figure 4: qPCR primer optimisation results of *MMP-13* gene (A) Amplification curve results on qPCR and (B) Homogeneous melting peak graphs from the results of qPCR

MMP-13 gene expression

A preliminary analysis (normality and homogeneity tests) was performed before the ANOVA test. Normality test with Saphiro Wilk Test showed a significant result (≥ 0.05 , data was normally distributed) in all treatment group.




Figure 5: qPCR primer optimisation results of *RELA* gene (A) Amplification curve results on qPCR and (B) Homogeneous melting peak graphs from the results of qPCR

Descriptive analysis with Skewness ratio < 2 in all treatment groups. Homogeneity test with the

Levene test was $0.18 \geq 0.05$, showed that data of *MMP-13* have the same (homogeneous) variant.




Figure 6: Results of the primer optimisation on electrophoresis of the *MMP-13* gene

The analysis was continued to ANOVA test and then Post Hoc Tukey's HSD Test. Anova test for *MMP-13* gene expression was $F = 5.963$ with a significance value ($0.002 \leq 0.05$). There are significant differences between treatment groups. Based on the results, analysis of Tukey's HSD Post Hoc Test was continued to find the differences between groups.




Figure 7: Results of the primer optimisation on electrophoresis of the *RELA* gene

Table 1 summarises the results of the ANOVA test and the differences between treatment groups summarised in Table 2.




Figure 8: Gene Expression (A) *MMP-13* and (B) *RELA*

The highest gene expression of *MMP-13* was in Group I and II (1.00 ng/μl), followed by Group III (0.41 ng/μl), Group IV (0.24 ng/μl), Group V (0.13 ng/μl), and Group VI (0.04 ng/μl).

Table 1: *MMP-13* gene expression level toward several treatment groups in OA

Groups	<i>MMP-13</i> gene expression (ng/μl)	
	Average	p-value
Group I	1.00 ± 0.00	0.002
Group II	1.00 ± 0.00	
Group III	0.41 ± 0.13	
Group IV	0.24 ± 0.03	
Group V	0.13 ± 0.04	
Group VI	0.04 ± 0.01	

Description: Group I = Synovocyte control incubated for 24 hours; Group II = Synovocyte control incubated for 48 hours; Group III = Mesenchymal Stem Cell Wharton Jelly (MSC-WJ) incubated for 24 hours; Group IV = Mesenchymal Stem Cell Wharton Jelly (MSC-WJ) incubated for 48 hours; Group V = Synovocyte MSC-WJ co-culture incubated for 24 hours; Group VI = Synovocyte MSC-WJ co-culture incubated for 48 hours.

The treatment group shows significant differences in *MMP-13* gene expression between groups I, III, IV, V and VI, whereas there was no significant difference between groups I and II ($p < 0.05$).

Table 2: Analysis of the effect of MSC-WJ administration toward *MMP-13* gene expression (ng/μl)

Groups	<i>MMP-13</i> gene expression (ng/μl)					
	I	II	III	IV	V	VI
I	-	1.00	0.00	0.00	0.00	0.00
II	1.00	-	0.00	0.00	0.00	0.00
III	0.00	0.00	-	0.11	0.00	0.00
IV	0.00	0.00	0.11	-	0.06	0.00
V	0.00	0.00	0.00	0.06	-	0.00
VI	0.00	0.00	0.00	0.06	0.00	-

*) Significantly different ($p < 0.05$).

RELA Gene Expression

A normality and homogeneity tests were performed before the ANOVA test. Normality test with Saphiro Wilk Test showed a significant result (≥ 0.05 , data was normally distributed) in all treatment group. Descriptive analysis with Skewness ratio < 2 in all treatment groups. Homogeneity test with Levene test was $0.013 \geq 0.05$, showed that data of *MMP-13* were not homogeneous. The analysis was continued to non-parametric test (Kruskal Wallis test), Mann Whitney test was done if the different was significant.

The highest gene expression of *RELA* gene was in Group I and II (1.00 ng/μl), Group V (0.67 ng/μl), Group III (0.58 ng/μl), Group IV (0.16 ng/μl), and Group VI (0.16 ng/μl) (Table 3). Analysis of MSC-

WJ administration toward *RELA* gene expression among treatment groups was presented in Table 3.

Table 3: Analysis of the effect of MSC-WJ administration toward *RELA* gene expression (ng/ μ l) with Mann Whitney test

Groups	<i>RELA</i> gene expression (ng/ μ l)					
	I	II	III	IV	V	VI
I	-	1.00	0.01	0.01	0.01	0.01
II	1.00	-	0.01	0.01	0.01	0.01
III	0.01	0.01	-	0.02	0.25	0.02
IV	0.01	0.01	0.02	-	0.02	1.00
V	0.01	0.01	0.25	0.02	-	0.02
VI	0.01	0.01	0.02	1.00	0.02	-

*) Significantly different ($p < 0.05$)

There were significant different in *RELA* gene expression between groups I with groups III, IV, V and VI ($p < 0.05$), whereas there was no significant different ($p > 0.05$) between groups I and II (MSC-WJ administration no affected *RELA* gene expression in 24 and 48-hour synoviocyte group ($p > 0.05$)). The expression of *RELA* gene between group II and group III, IV, V, VI was significantly different ($p < 0.05$) [6] *RELA* gene expression in group II was higher than group III, IV, V and VI as shown in Table 4.

Table 4: Analysis of the effect of MSC-WJ administration toward *MMP-13* gene expression (ng/ μ l)

Groups	<i>RELA</i> gene expression (ng/ μ l) (ng/ μ l)	
	Average	p-value
Group I	1.00 \pm 0.00	0.001
Group II	1.00 \pm 0.00	
Group III	0.58 \pm 0.04	
Group IV	0.16 \pm 0.04	
Group V	0.67 \pm 0.10	
Group VI	0.16 \pm 0.01	

Description: Group I = Synoviocyte control incubated for 24 hours; Group II = Synoviocyte control incubated for 48 hours; Group III = Mesenchymal Stem Cell Wharton Jelly (MSC-WJ) incubated for 24 hours; Group IV = Mesenchymal Stem Cell Wharton Jelly (MSC-WJ) incubated for 48 hours; Group V = Synoviocyte MSC-WJ co-culture incubated for 24 hours; Group VI = Synoviocyte MSC-WJ co-culture incubated for 48 hours.

The expression of *RELA* gene between group III and group V was not significantly different ($p > 0.005$), whereas between group III and groups I, II, IV and VI, the expression of *RELA* was significantly different ($p < 0.05$). The expression of *RELA* gene in group III was higher than groups IV and VI, but lower than groups I, II and V.

There was a significantly different ($p < 0.05$) between group IV with groups I, II, III and V. *RELA* gene expression between group IV and group VI was not significant ($p > 0.05$), expression level in group IV was lower than group I, II, III and V, but similar to group VI (Table 4). *RELA* gene expression between group V with groups I, II, IV and VI was significantly different ($p < 0.05$), but not for group III ($p > 0.05$). *RELA* gene expression level in group V was higher than groups III, IV and VI, but lower than groups I and II. *RELA* gene expression between group VI and groups I, II, III and V were statistically different ($p < 0.05$). The gene expression in group VI was lower than groups I, II, III and V, while group IV was not significantly different ($p > 0.05$). The expression in group VI was lower than groups I, II, III and V. The expression level of *RELA* genes in groups IV and VI was similar.

Discussion

In the present study, the lowest *MMP-13* gene expression was shown in group VI (48 hours synoviocyte MSC-WJ co-culture group). The results of this study showed that MSC-WJ culture in synoviocyte OA after 48 hours reduced *MMP-13* gene expression by 0.04 times compared to the control group, whereas in group V (24 hours MSC-WJ cell culture) synoviocyte culture) reduced gene expression *MMP-13* in OA synoviocyte cells was 0.13 times compared to the control group ($p < 0.05$).

From the results of Tukey's Test, HSD in Table 1, there were not significantly different between 24 and 48 hours synoviocyte control groups. *MMP-13* is released in synoviocyte of OA when inflammation occurs. According to Li, et al., 2011 it is said that when compared with other types of MMP, *MMP-13* is an important target gene during the development of OA because *MMP-13* gene expression is specifically found in cartilages and no *MMP-13* expression is found in normal patient cartilages [7].

In MSC-WJ culture group for 24 and 48 hours, the *MMP-13* gene was expressed (the result of electrophoresis). Almaki and Agrawal (2016) revealed that MMP plays an important role in the process of proliferation, migration, angiogenesis and differentiation of mesenchymal stem cells. *MMP-13* gene expression increases in the process of chondrogenic and osteogenic differentiation of Mesenchymal Stem Cell [8]. The previous study conducted by Mannello et al., (2006) investigated the role and function of MMP in the process of differentiation and characterisation of Mesenchymal Stem Cell, *MMP-13* is also involved in the initial phase of the differentiation process from MSC [9]. In the differentiation process of MSC into chondrocytes, *MMP-13* gene expression increases, but the specific mechanism is still unknown [10].

The results of the Tukey test for 24- and 48-hour synoviocyte-MSC-WJ co-culture groups showed significantly different compared to the control of synoviocyte. Weiss et al., (2017) found that meniscus cells co-cultured with MSC significantly reduce *MMP-13* gene expression. The results of the study found that *MMP-13* gene expression in 48 hours synoviocyte MSC-WJ co-culture group was lower than 48 hours synoviocyte MSC-WJ co-culture group [11].

RELA gene expression

In the current study, the lowest gene expression of *RELA* was in group VI (a treatment group of synoviocyte and MSC-WJ co-culture for 48 hours). The result was by the initial hypothesis that MSC-WJ decreases the expression of *RELA* gene. *RELA* gene expression in 48-hour synoviocyte and MSC-WJ co-culture group decreased 0.16 times

relatively lower compared to the control group, whereas in group V which was the co-culture treatment group of synoviocyte and MSC-WJ cells during 24 hours decreased by 0.67 times relatively lower than the control group.

In the initial inflammatory process, *RELA* gene as a sub-family of NF- κ B is involved in the expression of several genes that play a role in the inflammatory response. The transcription of NF- κ B is stimulated by pro-inflammatory cytokines and chemokines. Activation of NF- κ B triggers the expression of genes to induce articular joint damage resulting in osteoarthritis. In line with Tortatore et al., (2012) reported that low value of Δ Cq in synoviocyte OA control group increases *RELA* gene expression [12]. NFKB activity will be high during the initial formation of new bones, including cartilage, but will decrease after the bones become mature [13]. High expression levels of *RELA* gene in 24-hour MSC-WJ co-culture group showed that NF- κ B plays a role in the differentiation and self-renewal processes of MSC-WJ [14]. Most of the pro-inflammatory effects of interferon γ and TNF- α are induced through NF- κ B translocation; the pathway is also modulated by MSC. Wen et al., (2014) stated that the expression of *NF- κ B p-65 gene (RELA)* increased significantly in the first 24 hours and 48 hours [15]. NF- κ B activity is high during the initial formation of new bone, including cartilage, but will decrease after the bone is mature [13].

The relative expression of *RELA* gene in 48-hour synoviocyte MSC-WJ co-culture group was significantly lower than the 24-hour synoviocyte MSC-WJ co-culture group. The result was due to the effect of MSC-WJ immunomodulatory which has begun to work on synoviocyte OA to control NF- κ B gene. Wen et al. (2014) reported that bone marrow-derived Mesenchymal Stem Cells modulate the effects of pro-inflammatory cytokines on human corneal epithelial cells. This study explained that the influence of MSC-WJ on synoviocyte of OA toward the parameters of MMP-13 and *RELA* genes expression as a subfamily of NF- κ B gene sub-unit p65. In general, MSC-WJ can reduce the expression of MMP-13 and *RELA* genes which are pro-inflammatory cytokines in osteoarthritis. The results of the study are useful as a reference for the use of stem cells, especially for MSC-WJ as a promising OA therapy in the future [15].

This study concluded that MSC-WJ in OA synoviocyte significantly reduced the expression of *MMP-13* and *RELA* gene ($p < 0.05$).

Acknowledgement

The authors thank Andalas Cancer Research Center and Stem Cell (ACRC) and Biomedical Laboratory, Faculty of Medicine, Andalas University

and Indonesian Medical Education and Research Institute (IMERI), Faculty of Medicine, University of Indonesia.

References

- Price SA, Wilson LM. Patofisiologi konsep klinis proses-proses penyakit. Jakarta, EGC, ed VI, 2013.
- WHO. The global burden of disease 2004 Update. WHO Press, Switzerland, 2004.
- Ahmed S, Anuntiyo J, Malemud CJ, Haqqi TM. Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: a review. Evid Based Complement Alternat Med. 2005; 2(3):301-8. <https://doi.org/10.1093/ecam/neh117> PMID:16136208 PMCID:PMC1193557
- Roman-Blas JA, Jimenez SA. NF- κ B as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis and cartilage. 2006; 14(9):839-48. <https://doi.org/10.1016/j.joca.2006.04.008> PMID:16730463
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta$ CT method. methods. 2001; 25(4):402-8. <https://doi.org/10.1006/meth.2001.1262> PMID:11846609
- Razali NM and Wah YB. Power comparison of Saphiro Wilk, Kolmogorov- Smirnov, Lilefors and Anderson Dring-test. Faculty of Computer and Mathematical Science, University Technology MARA., 2017.
- Li NG, Shi ZH, Tang YP, Wang ZJ, Song SL, Qian LH, Qian DW, Duan JA. New hope for the treatment of osteoarthritis through selective inhibition of MMP-13. Current medicinal chemistry. 2011; 18(7):977-1001. <https://doi.org/10.2174/092986711794940905>
- Almalki SG, Agrawal DK. Effects of matrix metalloproteinases on the fate of mesenchymal stem cells. Stem cell research & therapy. 2016; 7(1):129. <https://doi.org/10.1186/s13287-016-0393-1> PMID:27612636 PMCID:PMC5016871
- Manello F, Tonti GAM, Bagnara GP, Papa S. Role and function matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. The stem cell niche : Consise Review. 2006; 24:475-481. <https://doi.org/10.1634/stemcells.2005-0333> PMID:16150919
- Li H, Wang D, Yuan Y, Min J. New insights on the MMP-13 regulatory network in the pathogenesis of early osteoarthritis. Arthritis research & therapy. 2017; 19(1):248. <https://doi.org/10.1186/s13075-017-1454-2> PMID:29126436 PMCID:PMC5681770
- Weiss WM, Mulet-Sierra A, Kunze M, Jomha NM, Adesida AB. Coculture of meniscus cells and mesenchymal stem cells in simulated microgravity. NPJ Microgravity. 2017; 3(1):28. <https://doi.org/10.1038/s41526-017-0032-x> PMID:29147680 PMCID:PMC5681589
- Tomatore L, Thotakura AK, Benrett J, Morelli M, Franzoso G. The nuclear factor kappa beta signaling pathway: Integrating metabolism with inflammation; Trends in Cell Biology. 2012; 22(11):557-566. <https://doi.org/10.1016/j.tcb.2012.08.001> PMID:22995730
- Krum SA, Chang J, Miranda-Carboni G, Wang CY. Novel functions for NFkB: inhibition of bone formation. Nature Reviews Rheumatology. 2010; 6(10):607-611. <https://doi.org/10.1038/nrrheum.2010.133> PMID:20703218 PMCID:PMC3078572
- Yang ZX, Han ZB, Ji YR, Wang YW, Liang L, Chi Y, et al. CD106 identifies a subpopulation of mesenchymal stem cells with unique immunomodulatory properties. PLoS One. 2013; 8(3):e59354. <https://doi.org/10.1371/journal.pone.0059354> PMID:23555021 PMCID:PMC3595282
- Wen I, Zhu M, Petsoglou C. Differentiation and immunomodulatory effects of bone marrow-derived mesenchymal stem cell on human corneal epithelium. Chin J Cell. 2014; 4:105-15.

The Influence of Wharton Jelly Mesenchymal Stem Cell toward Matrix Metalloproteinase-13 and RELASynoviocyte Gene Expression on Osteoarthritis

ORIGINALITY REPORT

6%

SIMILARITY INDEX

7%

INTERNET SOURCES

11%

PUBLICATIONS

0%

STUDENT PAPERS

PRIMARY SOURCES

1

doaj.org

Internet Source

3%

2

journal.uad.ac.id

Internet Source

3%

Exclude quotes On

Exclude matches < 3%

Exclude bibliography On